Company:Duearity

From HandWiki
Duearity AB
FormerlyCochlearity
TypePublic (Aktiebolag)
IndustryMedical equipment  ·
Tinnitus treatment
DefunctSeptember 10, 2024 (2024-09-10) [1][2]
Headquarters
Malmö
,
Sweden
Key people
ProductsTinearity G1
Tinearity AI
Websitewww.duearity.com
Footnotes / references
[3][4][5][6][7][8][9][10]

Duearity was a Swedish medical technology company based in Malmö.[11][12][13] The company specialised in hardware and software for tinnitus treatment. From May 2021 to September 2024, Duearity was publicly traded on the Nasdaq First North stock exchange.[14][15][16]

Origins

Peter Arndt, one of Duearity's founders, was undergoing tinnitus retraining therapy (TRT) and noticed the treatment to be effective, but incompatible with daily life. Tinnitus retraining therapy is based on cognitive behavioral therapy and requires white noise to be played uninterrupted for 6-8 hours per day for 6-24 months. Wearing headphones for prolonged and uninterrupted period of time was interfering with work during daytime and with sleep during nighttime.

The founders set out to find a solution that did not require headphones and did not occupy the ear canals.[17][18][3] In 2020, a proof of concept was successfully completed and the company applied for a patent.[19][20]

IPO

On 11 May 2021, the company's shares debuted on Nasdaq First North under ticker symbol DEAR. The company was previously called Cochlearity, but the name was changed pre-IPO in order to avoid mixup with another medtech company.[21]

75,3% of the IPO shares were subscribed before the IPO offer was made public.[22][23] Duearity’s IPO was oversubscribed by 9 times.[24]

Products and market

Duearity is focusing its products on white noise and tinnitus retraining therapy, which has been shown to be effective in a variety of research studies.[25][26][27][28]

Since 2020, Duearity has been developing the world's smallest and most flexible tinnitus aid that emits white noise through bone conduction technology.[29][30] It is a patented medtech CE class IIa product[31][32] with FDA 510(k) clearance in the U.S.[33][34] It is a non-invasive device that attaches behind the ears and keeps the ear canals free.

Duearity is also developing a software for analysing tinnitus and managing its symptoms.[35] The company observes strong interest from researchers, audiologists and otorhinolaryngologists.[20]

References

  1. ↑ "Duearity AB (publ) i konkurs" (in sv). 2024-09-23. https://ir.duearity.com/for-investerare/pressreleaser/detail/?slug=duearity-ab-publ-i-konkurs. 
  2. ↑ "First North-listade Duearity handelsstoppad – ska ansöka om konkurs" (in sv). 2024-09-06. https://www.di.se/live/first-north-listade-duearity-handelsstoppad-ska-ansoka-om-konkurs/. 
  3. ↑ 3.0 3.1 Annual Report 2021: arsredovisning-2021-duearity-ab-signerad.pdf , accessdate: 6 december 2022
  4. ↑ MedTech Magazine: Cochlearity blir Duearity inför börsnotering - MedTech Magazine , accessdate: 6 december 2022
  5. ↑ Nasdaq: DEAR, Duearity, (SE0015949482) - Nasdaq , accessdate: 6 december 2022
  6. ↑ Bolagsverket: Sök företagsinformation Företag - Sök företagsinformation, accessdate: 6 december 2022
  7. ↑ Skatteverket: Duearity AB | Skatteverket , accessdate: 6 december 2022
  8. ↑ The Wall Street Journal: Duearity DEAR.SE | Duearity AB Financial Statements - WSJ , accessdate: 6 december 2022
  9. ↑ "Duearity Aktie" (in sv). Dagens industri. 2022-12-15. https://www.di.se/bors/aktier/dear-5441090/. 
  10. ↑ "Delisting of Duearity AB (publ) from Nasdaq First North Growth Market". 2024-09-10. https://view.news.eu.nasdaq.com/view?id=b758a541d85b743297edefa14553cb1a8&lang=en. 
  11. ↑ Göransson, Anders (2024-09-11). "Tidigare börsraketen i konkurs – "Fortsatt drift inte möjlig"" (in sv). https://www.medtechmagazine.se/article/view/1117414/tidigare_borsraketen_i_konkurs_fortsatt_drift_inte_mojlig. 
  12. ↑ Gisborn, Linus (2024-09-13). "VD:ns hårda ord efter konkursen: "Förväxta bebisinvesterare"" (in sv). https://www.affarsvarlden.se/artikel/vdns-harda-ord-efter-konkursen-forvaxta-bebisinvesterare. 
  13. ↑ "Duearity" (in sv). 2021-05-11. https://www.skatteverket.se/privat/skatter/vardepapper/aktiehistorik/d/duearity.4.3016b5d91791bf5467912de.html. 
  14. ↑ Nasdaq: Listing of Duearity AB (publ), on Nasdaq First North Growth Market (203/21) | Nasdaq, accessdate: 6 december 2022
  15. ↑ Hörselbolaget Duearity till First North: Hörselbolaget Duearity till First North , accessdate: 6 december 2022
  16. ↑ Affärsvärlden: Duearity - IPO | Affärsvärlden , accessdate: 6 december 2022
  17. ↑ Digital Health Technology News: Swedish MedTech startup starts pre-sale of unique product for tinnitus treatment - Digital Health Technology News , accessdate: 6 december 2022
  18. ↑ MedTech Magazine: Malmöbolag lanserar produkt för egenbehandling av tinnitus - MedTech Magazine , accessdate: 6 december 2022
  19. ↑ "Duearity AB:s halvårsrapport för perioden 1 januari till 30 juni 2021" (in sv). 2021-08-25. https://view.news.eu.nasdaq.com/view?id=b3b414d08e5307c8a205ae0af800d7661&lang=sv. 
  20. ↑ 20.0 20.1 "Duearity 2022 Q3" (in sv). https://storage.mfn.se/0352446f-2290-4fd0-bdce-7542b5443896/q3-2022-duearity-ab.pdf. 
  21. ↑ MedTech Magazine: Cochlearity blir Duearity inför börsnotering - MedTech Magazine , accessdate: 6 december 2022
  22. ↑ "IPO Guide: Duearity". Affärsvärlden. https://www.affarsvarlden.se/ipo-guiden/bolag/duearity. 
  23. ↑ Liedholm, Kim (2021-04-20). "Duearity vill hjälpa personer med tinnitusbesvär" (in sv). https://www.biostock.se/2021/04/duearity-vill-hjalpa-personer-med-tinnitusbesvar/. 
  24. ↑ "Duearitys emission kraftigt övertecknad" (in sv). 2021-04-30. https://www.dagensps.se/bors-finans/borsnoteringar/duearitys-emission-kraftigt-overtecknad/. 
  25. ↑ "Clinical efficacy of tinnitus retraining therapy and cognitive behavioural therapy in the treatment of subjective tinnitus: a systematic review". J Laryngol Otol 128 (12): 1028–33. December 2014. doi:10.1017/S0022215114002849. PMID 25417546. 
  26. ↑ "The effect of tinnitus retraining therapy on chronic tinnitus: A controlled trial". Laryngoscope Investig Otolaryngol 2 (4): 166–177. August 2017. doi:10.1002/lio2.76. PMID 28894836. 
  27. ↑ "Tinnitus retraining therapy: prognosis factors". Am J Otolaryngol 28 (4): 225–9. 2007. doi:10.1016/j.amjoto.2006.09.004. PMID 17606035. 
  28. ↑ "Efficacy of tinnitus retraining therapy in the treatment of tinnitus: A meta-analysis and systematic review". Am J Otolaryngol 42 (6). 2021. doi:10.1016/j.amjoto.2021.103151. PMID 34303210. 
  29. ↑ BioStock: Duearity vill hjälpa personer med tinnitusbesvär - BioStock , accessdate: 6 december 2022
  30. ↑ Duearity ska noteras på Nasdaq First North den 11 maj: Duearity ska noteras på Nasdaq First North den 11 maj , accessdate: 6 december 2022
  31. ↑ Svensk Patentdatabas, Träfflista: Svensk Patentdatabas, Träfflista , accessdate: 6 december 2022
  32. ↑ PRV avser att godkänna Duearitys patentansökan: PRV avser att godkänna Duearitys patentansökan , accessdate: 6 december 2022
  33. ↑ "510(k) Notification". 2002-11-01. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K223694. 
  34. ↑ "510(k) Summary". 2024-05-24. https://www.accessdata.fda.gov/cdrh_docs/pdf22/K223694.pdf. 
  35. ↑ "Swedish Patent Database, Results list". 2020-07-27. https://tc.prv.se/spd/search?content=&number=544905&numberflag=&klass=&from=&to=&dateflag=&prionr=&applicant=&inventor=&representative=&cityzip=&cityzipflag=&tidnrtyp=&tidar_from=&tidnr_from=&tidar_tom=&tidnr_tom=&inforce=&system=&lang=en&hits=true&tab=2. 

Further reading

See also



Retrieved from "https://handwiki.org/wiki/index.php?title=Company:Duearity&oldid=4017234"